Puma Biotechnology | PBYI - Koszty Sprzedaży





Koszty Sprzedaży Zmiana Data
Agios Pharmaceuticals USD 1.88M 199K 2025-12
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
Amgen USD 1.79B 128M 2025-12
Biogen USD 810.1M 205.1M 2025-09
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Daiichi Sankyo JPY 118.28B 37.7B 2025-12
Esperion Therapeutics USD 51.63M 22.2M 2024-09
Exelixis USD 26.48M 7.91M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
Glaxosmithkline GBP 3.01B 853.01M 2025-09
Incyte USD 121.18M 22.18M 2025-12
MacroGenics USD 44.3M 5.4M 2025-09
Moderna USD 452M 245M 2025-12
Novartis USD 3.54B 217M 2025-09
Pfizer USD 6.29B 2.12B 2025-12
PTC Therapeutics USD 16.3M 7.02M 2025-12
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 584.6M 63M 2025-12
Roche Holding CHF 8.48B 4.61B 2025-12
Sangamo BioSciences 2.42M 1.11M 2024-06
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Takeda JPY 401.15B 184.07B 2025-12
TG Therapeutics USD 38.14M 10.05M 2025-12
Ultragenyx Pharmaceutical USD 29M 1.01M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Vertex Pharmaceuticals USD 466M 51.2M 2025-12